ConductScience.org, home

Paper36977782

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.

Ussher JR and 1 other. Nat Rev Cardiol, 2023. Cited by 479 papers, by iCite.

Cite this record

ConductScience Library. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Papers, record 36977782. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36977782

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
PubMed
Journal
Nat Rev Cardiol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
479
iCite
Relative citation ratio, by iCite
52
iCite
Revised in PubMed
2026-10-31
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ussher JRJohn Rhttps://orcid.org/0000-0001-9574-5707
2Drucker DJDaniel Jhttps://orcid.org/0000-0001-6688-8127

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Cardiovascular SystemMajor topic
Cardiovascular DiseasesMajor topic
Humans
Hypoglycemic Agents
Glucagon-Like Peptide 1
Obesity
Glucagon-Like Peptide-1 Receptor Agonists

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06877572Weight Loss Management in Endometrial Cancer SurvivorsBackground

Source ClinicalTrials.gov

Download CSV of trials

References126

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136545339Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/36545339PubMed
235907261Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.Endocr Rev2023https://conductscience.org/library/papers/35907261PubMed
336027914Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation.Cell Metab2022https://conductscience.org/library/papers/36027914PubMed
417098089The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Lancet2006https://conductscience.org/library/papers/17098089PubMed
528249135Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med2017https://conductscience.org/library/papers/28249135PubMed
629091756Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion.Cell Rep2017https://conductscience.org/library/papers/29091756PubMed
729217412Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.J Clin Lipidol2018https://conductscience.org/library/papers/29217412PubMed
826432951Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.J Mol Cell Cardiol2015https://conductscience.org/library/papers/26432951PubMed
933983836Cardiac Energy Metabolism in Heart Failure.Circ Res2021https://conductscience.org/library/papers/33983836PubMed
1030384842
Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.
Cardiovasc Diabetol2018https://conductscience.org/library/papers/30384842PubMed
1129444223GLP-1 Receptor Expression Within the Human Heart.Endocrinology2018https://conductscience.org/library/papers/29444223PubMed
1235958685Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation.JACC Basic Transl Sci2022https://conductscience.org/library/papers/35958685PubMed
1333320179Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation.Endocr Rev2021https://conductscience.org/library/papers/33320179PubMed
1425414155Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.Diabetes Care2015https://conductscience.org/library/papers/25414155PubMed
1523868944
Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
Arterioscler Thromb Vasc Biol2013https://conductscience.org/library/papers/23868944PubMed
1633446799Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better.Sci Rep2021https://conductscience.org/library/papers/33446799PubMed
1719627582Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.BMC Cardiovasc Disord2009https://conductscience.org/library/papers/19627582PubMed
1825735732GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R.Diabetes2015https://conductscience.org/library/papers/25735732PubMed
1919195607Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.J Am Coll Cardiol2009https://conductscience.org/library/papers/19195607PubMed
2024296712Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.Diabetes2014https://conductscience.org/library/papers/24296712PubMed

See all 126 referencesDownload CSV of references

Cited by298

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 479 citations.

PMIDTitleJournalYearIn PapersSource
42979257Type 2 diabetes and the cardio-renal-metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists.touchREV Endocrinol2026https://conductscience.org/library/papers/42979257PubMed
42947001Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database.BMC Cardiovasc Disord2026https://conductscience.org/library/papers/42947001PubMed
42941702GLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations.J Clin Med2026https://conductscience.org/library/papers/42941702PubMed
42936196Real-world effectiveness of liraglutide in children with type 2 diabetes.J Endocr Soc2026https://conductscience.org/library/papers/42936196PubMed
42878985GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.Curr Atheroscler Rep2026https://conductscience.org/library/papers/42878985PubMed
42865473GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials.Front Med (Lausanne)2026https://conductscience.org/library/papers/42865473PubMed
42857051Baseline BMI and weight change in dilated cardiomyopathy: associations with LVEF, BNP, and NYHA class.Front Cardiovasc Med2026https://conductscience.org/library/papers/42857051PubMed
42851902Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42851902PubMed
42812847Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.J Endocr Soc2026https://conductscience.org/library/papers/42812847PubMed
42775225Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42775225PubMed
42746268Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data.Mayo Clin Proc Digit Health2026https://conductscience.org/library/papers/42746268PubMed
42713454Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant.Gastroenterol Hepatol (N Y)2026https://conductscience.org/library/papers/42713454PubMed
42709280Effects of heart failure pharmacotherapy on natriuresis and diuresis: A narrative review.Heart Fail Rev2026https://conductscience.org/library/papers/42709280PubMed
42669711
Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes.
Nat Commun2026https://conductscience.org/library/papers/42669711PubMed
42642762
Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.
Cardiovasc Diabetol2026https://conductscience.org/library/papers/42642762PubMed
42642357Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.Diabetes Obes Metab2026https://conductscience.org/library/papers/42642357PubMed
42630726Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy.Front Urol2026https://conductscience.org/library/papers/42630726PubMed
42629417Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42629417PubMed
42612051Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.J Clin Pharmacol2026https://conductscience.org/library/papers/42612051PubMed
42598740Reply.Arthritis Rheumatol2026https://conductscience.org/library/papers/42598740PubMed

See all 298 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36977782

GET https://conductscience.org/api/papers/v1/36977782/references?page=2